The city of Vienna wants to be the first federal state to use two drugs to combat the pandemic in addition to vaccination. The health authority has developed its own system for this and will test the treatment of infected risk patients who are not in the hospital in a one-month trial phase. The infusion with sotrovimab, which is already used in hospital, and the preparation molnupiravir, which is to be taken in tablet form, are used. 2000 packs of these were made available to the city by the federal government in a first tranche, it is constantly being reordered and replenished.
Hospitalization should be prevented
should be treated with it people who tested positive and are at increased risk of a severe course in the early phase of the disease. City Councilor for Health Peter Hacker, Covid-19 project manager Ursula Karnthaler and Michael Binder, the medical director of the Vienna Health Association, explained exactly how the administration will take place. The plan is:
- Via a specially created telemedicine center, contact tracing proactively contacts people who are considered risk patients, especially older people, and medically explains the possibility of therapy.
- If the infusion is used, an ambulance picks up the patient and takes him to the Covid 19 infusion outpatient clinic in the clinic Favorites and after the treatment back home.
Medication does not replace vaccination under any circumstances
112 packs of the drug, which changes viral metabolism and thus limits the multiplication of viruses in the body, have already been delivered. “According to initial studies, the risk of hospital admission can be reduced by a third,” says Michael Binder. City Councilor Hacker emphasizes that medicine in no way replaces vaccination, which works much better: “The medicines are not as good as expected, but better than no treatment,” he plans to steadily expand the supply. For example, that specialists can also report which of their patients is eligible for treatment.
- It is not possible to take it during pregnancy and breastfeeding.
Men should not father a child for the duration of treatment and for three months thereafter.
Side effects may include diarrhea, dizziness and headaches.
Approval expected in February Molnupiravir has not yet been approved by the European Medicines Agency (EMA), this is expected in February. Other drugs, such as Paxlovid, are also expected to be used soon.
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here